Table 3.
Summary of clinical characteristics of the patients with hemoptysis
| Factor | Events | Case ratio (distribution ratio) |
|---|---|---|
| Total | 23 | 100.0 |
| Volume of bloody sputum | ||
| Large amount | 15 | 65.2 |
| Small amount | 5 | 21.7 |
| Unknown/not recorded | 3 | 13.0 |
| Degree of hemoptysis (grade) | ||
| 2 | 4 | 17.4 |
| 3 | 4 | 17.4 |
| 4 | 1 | 4.3 |
| 5 | 14 | 60.9 |
| Unknown/not recorded | 0 | 0.0 |
| Time from initial administration of bevacizumab to hemoptysis onset (weeks) | ||
| <3 | 3 | 13.0 |
| ≥3 – <24 | 16 | 69.6 |
| ≥24 | 4 | 17.4 |
| Unknown/not recorded | 0 | 0.0 |
| Fundamental statistics | ||
| Mean (standard deviation) | 13.1 (12.33) | |
| Median (range) | 7.0 (1–41) | |
| Hemoptysis outcome | ||
| Recovered/improved | 8 | 34.8 |
| Not recovered | 0 | 0.0 |
| Sequela | 1 | 4.3 |
| Death | 14 | 60.9 |
| Unknown/not recorded | 0 | 0.0 |
| Seriousness | ||
| Non‐serious | 3 | 13.0 |
| Serious | 20 | 87.0 |
| Causal relationship | ||
| Bevacizumab | ||
| Related | 7 | 30.4 |
| Probably related | 6 | 26.1 |
| Possibly related | 10 | 43.5 |
| Factors other than bevacizumab (>1 response possible) | ||
| Primary disease | 15 | |
| Concurrent disease/medical history | 1 | |
| Concomitant drug/concomitant therapy | 5 | |
| Other | 6 | |